GLP1R and type 2 diabetes mellitus: They have been highly effective in helping patients with T2D meet glycemic targets,1 achieve substantial weight loss,2 and improve cardiometabolic and kidney outcomes in high-risk subgroups.3,4,5,6,7 As a result, the American Diabetes Association recommends GLP-1 RAs as 1 of 2 possible first-line therapies for patients with T2D who have, or are at high risk for, atherosclerotic cardiovascular disease.8